Janssen reports positive data from plaque psoriasis drug trial

Janssen has announced the findings of two clinical trials that demonstrate the effectiveness of its new plaque psoriasis drug guselkumab.

Data from the phase III VOYAGE 2 study showed that patients with moderate to severe plaque psoriasis who were treated with guselkumab experienced significant improvements in skin clearance and other measures of disease activity compared with placebo.

The drug also showed a better performance than an established anti-TNF therapy, making this the second phase III study to demonstrate superior efficacy of guselkumab following similar results from VOYAGE 1.

Meanwhile, the company also announced the results of another phase III trial called NAVIGATE, showing that patients who had an inadequate response following treatment with Stelara showed significant improvement after switching to guselkumab.

Dr Newman Yeilding, head of immunology development at Janssen Research and Development, said: "Data from the phase III VOYAGE 2 and NAVIGATE studies continue to demonstrate the potential that guselkumab may offer patients and physicians, and we are committed to working with health authorities around the world on our current and future applications."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.